

Literatuurlijst 2022

Publicaties gebaseerd op landelijke zoekvragen met gegevens uit PALGA

- 1. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.**
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M; HEBON Investigators, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hoening MJ.
Breast. 2022; 61:98-107.
- 2. Targeted RNA next generation sequencing analysis of cervical smears can predict the presence of hrHPV-induced cervical lesions.**
Andralojc KM, Elmelik D, Rasing M, Pater B, Siebers AG, Bekkers R, Huynen MA, Bulten J, Loopik D, Melchers WJG, Leenders WPJ.
BMC Med. 2022 Jun 9;20(1):206.
- 3. Safety and economic analysis of selective histopathology following cholecystectomy: multicentre, prospective, cross-sectional FANCY study.**
Bastiaenen VP, van Vliet JLP, de Savornin Lohman EAJ, Corten BJGA, de Jonge J, Kraima AC, Swank HA, van Acker GJD, van Geloven AAW, In 't Hof KH, Koens L, de Reuver PR, van Rossem CC, Slooter GD, Tanis PJ, Terpstra V, Dijkgraaf MGW, Bemelman WA; Dutch Snapshot Research Group.
Br J Surg. 2022; 109(4):355-362.
- 4. Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma.**
Belkouz A, Van Roessel S, Strijker M, van Dam JL, Daamen L, van der Geest LG, Balduzzi A, Cacciaguerra AB, van Dieren S, Molenaar Q, Groot Koerkamp B, Verheij J, Van Eycken E, Malleo G, Hilal MA, van Oijen MGH, Borbath I, Verslype C, Punt CJA, Besselink MG, Klümpen HJ; Dutch Pancreatic Cancer Group (DPCG).
Br J Cancer. 2022; 126(9):1280-1288.
- 5. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.**
Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, Spaander MCW, van Vuuren AJ, van Kemenade FJ, Ramakers CRB, Dekker E, Nagtegaal ID, Krul MF, Kok NFM, Kuhlmann KFD, Vink GR, van Leerdam ME, Elferink MAG; Dutch National Colorectal Cancer Screening Working Group.
Lancet Gastroenterol Hepatol. 2022; 7(1):60-68.
- 6. The use of histopathological subtyping in patients with ampullary cancer: a nationwide analysis.**
de Bakker J, Sommeijer D, Besselink M, Kazemier G, van Grieken N.
World J Surg Oncol. 2022; 20(1):406.
- 7. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients.**
de Bitter TJJ, de Reuver PR, de Savornin Lohman EAJ, Kroeze LI, Vink-Börger ME, van Vliet S, Simmer F, von Rhein D, Jansen EAM, Verheij J, van Herpen CML, Nagtegaal ID, Ligtenberg MJL, van der Post RS.
NPJ Precis Oncol. 2022; 6(1):83.

8. **Metastasis in the gallbladder: does literature reflect reality?**
de Bitter TJJ, Trapman DM, Simmer F, Hugen N, de Savornin Lohman EAJ, de Reuver PR, Verheij J, Nagtegaal ID, van der Post RS.
Virchows Arch. 2022; 480(6):1201-1209.
9. **Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.**
de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Jóźwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
J Clin Oncol. 2022; 40(21):2361-2374.
10. **Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial.**
de Jongh C, Triemstra L, van der Veen A, Brosens LAA, Luyer MDP, Stoot JHMB, Ruurda JP, van Hillegersberg R; LOGICA Study Group.
Gastric Cancer. 2022; 25(6):1060-1072.
11. **Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.**
de Krijger M, Carvalho B, Rausch C, Bolijn AS, Delis-van Diemen PM, Tijssen M, van Engeland M, Mostafavi N, Bogie RMM, Dekker E, Masclee AAM, Verheij J, Meijer GA, Ponsioen CY.
Inflamm Bowel Dis. 2022; 28(9):1309-1320.
12. **Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands.**
Deukeren DV, Heesterman BL, Roelofs L, Kiemeny LA, Witjes JA, Smilde TJ, Leenders GJLHV, Incrocci L, Vanneste BGL, Meijer RP, Siesling S, Bezooijen BPJV, Aben KKH; COVID and Cancer-NL consortium.
Cancer Treat Res Commun. 2022; 31:100553.
13. **Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.**
Dick S, Vink FJ, Heideman DAM, Lissenberg-Witte BI, Meijer CJLM, Berkhof J.
Br J Cancer. 2022;126(2):259-264.
14. **Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients.**
El Sharouni MA, Scolyer RA, van Gils CH, Ch'ng S, Nieweg OE, Pennington TE, Saw RP, Shannon K, Spillane A, Stretch J, Witkamp AJ, Sigurdsson V, Thompson JF, van Diest PJ, Lo SN.
Eur J Cancer. 2022; 167:133-141.
15. **The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness).**
El Sharouni MA, Rawson RV, Sigurdsson V, Witkamp AJ, van Gils CH, Scolyer RA, Thompson JF, van Diest PJ, Lo SN.
J Am Acad Dermatol. 2022; 87(2):298-305.
16. **Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes.**

- El Sharouni MA, Scolyer RA, van Gils CH, Ch'ng S, Nieweg OE, Pennington TE, Saw RPM, Shannon K, Spillane A, Stretch J, Witkamp AJ, Sigurdsson V, Thompson JF, van Diest PJ, Lo SN.
Eur J Cancer. 2022; 167:123-132.
17. **Interlaboratory Gleason grading variation affects treatment: a Dutch historic cohort study in 30 509 patients with prostate cancer.**
Flach RN, van Dooijeweert C, Aben KKH, Suelmann BBM, Willemse PM, van Diest PJ, Meijer RP.
J Clin Pathol. 2022; [Online ahead of print]
 18. **Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.**
Garcia BNC, van Kempen LC, Kuijpers CCHJ, Schuurin E, Willems SM, van der Wekken AJ.
Lung Cancer. 2022; 167:1-7.
 19. **Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study.**
Gorris M, van Huijgevoort NCM, Farina A, Brosens LAA, van Santvoort HC, Groot Koerkamp B, Bruno MJ, Besselink MG, van Hooft JE; Dutch Pancreatic Cancer Group.
Cancers (Basel). 2022; 14(17):4228.
 20. **External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice.**
Hamers PAH, Wensink GE, van Smeden M, Vink GR, Smabers LP, Lunenberg RA, Lacle MM, Koopman M, May AM, Roodhart JML.
Cancers (Basel). 2022; 14(20):5094.
 21. **Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.**
Heemskerk-Gerritsen BAM, Hollestelle A, van Asperen CJ, van den Beek I, van Driel WJ, van Engelen K, Gómez Garcia EB, de Hullu JA, Koudijs MJ, Mourits MJE, Hoening MJ, Boere IA.
PLoS One. 2022; 17(9):e0275015.
 22. **Mismatch repair deficiency and MUTYH variants in small intestine-neuroendocrine tumors.**
Helderman NC, Elsayed FA, van Wezel T, Terlouw D, Langers AMJ, van Egmond D, Kiliç G, Hristova H, Farina Sarasqueta A, Morreau H, Nielsen M, Suerink M; PALGA-group collaborators.
Hum Pathol. 2022; 125:11-17
 23. **In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.**
Hermans BCM, Derks JL, Hillen LM, van der Baan I, van den Broek EC, von der Thüsen JH, van Suylen RJ, Atmodimedjo PN, den Toom TD, Coumans-Stallinga C, Timens W, Dinjens WNM, Dubbink HJ, Speel EM, Dingemans AC; PALGA-group.
Int J Cancer. 2022; 150(5):802-815.
 24. **The prevalence of malignant melanoma in adults with mastocytosis and adnexal skin tumours: a case-control study.**
Hermans MAW, van Daele PLA, Damman J, van Doorn MBA, Pasmans SGMA.
Ann Cancer Epidemiol. 2022; 6:1.

25. **Vegetable and fruit consumption and cancer of unknown primary risk: results from the Netherlands cohort study on diet and cancer.**
Hermans KEPE, van den Brandt PA, Loef C, Jansen RLH, Schouten LJ.
BMC Cancer. 2022; 22(1):399.
26. **Incidence of ovarian cancer after bilateral salpingo-oophorectomy in women with histologically proven endometriosis.**
Hermens M, van Altena AM, Bulten J, van Vliet HAAM, Siebers AG, Bekkers RLM.
Fertil Steril. 2022; 117(5):938-945.
27. **Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.**
Hogenhout R, Osses DF, Alberts AR, Buizer-Rijksen HG, Remmers S, Roobol MJ.
BJU Int. 2022; [Online ahead of print]
28. **Real-world data of HER2-low metastatic breast cancer: A population based cohort study.**
Holthuis EI, Vondeling GT, Kuiper JG, Dezentjé V, Rosenlund M, Overbeek JA, van Deurzen CHM.
Breast. 2022; 66:278-284.
29. **The relationship between primary colorectal cancer histology and the histopathological growth patterns of corresponding liver metastases.**
Höppener DJ, Stook JPL, Galjart B, Nierop PMH, Nagtegaal ID, Vermeulen PB, Grünhagen DJ, Verhoef C, Doukas M; PALGA Group.
BMC Cancer. 2022; 22(1):911.
30. **Women with a positive high-risk human papillomavirus (HPV) test remain at increased risk of HPV infection and cervical precancer ≥15 years later.**
Inturrisi F, Bogaards JA, Siebers AG, Meijer CJLM, Heideman DAM, Berkhof J.
Tumour Virus Res. 2022; 14:200240.
31. **Using Explainable Machine Learning to Explore the Impact of Synoptic Reporting on Prostate Cancer.**
Janssen FM, Aben KKH, Heesterma BL, Voorham QJM, Seegers PA, Moncada-Torres A.
Algorithms. 2022; 15, 49.
32. **Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.**
Jenniskens JCA, Offermans K, Simons CCJM, Samarska I, Fazzi GE, van der Meer JRM, Smits KM, Schouten LJ, Weijenberg MP, Grabsch HI, van den Brandt PA.
J Cancer Res Clin Oncol. 2022; 148(10):2723-2742.
33. **Energy balance-related factors in childhood and adolescence and risk of colorectal cancer expressing different levels of proteins involved in the Warburg-effect.**
Jenniskens JCA, Offermans K, Simons CCJM, Samarska I, Fazzi GE, Smits KM, Schouten LJ, Weijenberg MP, Grabsch HI, van den Brandt PA.
Int J Cancer. 2022; 150(11):1812-1824.
34. **Mutations in the heparan sulfate backbone elongating enzymes EXT1 and EXT2 have no major effect on endothelial glycocalyx and the glomerular filtration barrier.**
Khalil R, Boels MGS; PALGA Group, van den Berg BM, Bruijn JA, Rabelink TJ, Hogendoorn PCW, Baelde HJ.
Mol Genet Genomics. 2022; 297(2):397-405

35. **Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity.**
Koomen BM, de Boer M, van Dooijeweert C, van Lindert ASR, Deckers IAG, Voorham QJM, Willems SM.
Virchows Arch. 2022; [Online ahead of print]
36. **Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort.**
Koopman B, Kuijpers CCHJ, Groen HJM, Timens W, Schuurin E, Willems SM, van Kempen LC.
Diagnostics (Basel). 2022; 12(3):668.
37. **Mismatch repair deficiency in early-onset duodenal, ampullary, and pancreatic carcinomas is a strong indicator for a hereditary defect.**
Kryklyva V, Brosens LA, Marijnissen-van Zanten MA, Ligtenberg MJ, Nagtegaal ID.
J Pathol Clin Res. 2022; 8(2):181-190.
38. **Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.**
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, Shah V, Hoogstraat M, Sei E, Mallo D, Roman-Escorza M, Ahmed AA, Xu M, van den Belt-Dusebout AW, Brugman W, Casasent AK, Clements K, Davies HR, Fu L, Grigoriadis A, Hardman TM, King LM, Krete M, Kristel P, de Maaker M, Maley CC, Marks JR, Menegaz BA, Mulder L, Nieboer F, Nowinski S, Pinder S, Quist J, Salinas-Souza C, Schaapveld M, Schmidt MK, Shaaban AM, Shami R, Sridharan M, Zhang J, Stobart H, Collyar D, Nik-Zainal S, Wessels LFA, Hwang ES, Navin NE, Futreal PA; Grand Challenge PRECISION consortium; Thompson AM, Wesseling J, Sawyer EJ.
Nat Genet. 2022; 54(6):850-860.
39. **Association of Cardiometabolic Disease With Cancer in the Community.**
Liu EE, Suthahar N, Paniagua SM, Wang D, Lau ES, Li SX, Jovani M, Takvorian KS, Kreger BE, Benjamin EJ, Meijers WC, Bakker SJL, Kieneker LM, Gruppen EG, van der Vegt B, de Bock GH, Gansevoort RT, Hussain SK, Hoffmann U, Splansky GL, Vasan RS, Larson MG, Levy D, Cheng S, de Boer RA, Ho JE.
JACC CardioOncol. 2022; 4(1):69-81.
40. **Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model.**
Meurs CJC, van Rosmalen J, Menke-Pluijmers MBE, Siesling S, Westenend PJ.
Ann Surg Oncol. 2022; [Online ahead of print]
41. **Diet quality indices and gastrointestinal cancer risk: results from the Lifelines study.**
Moazzen S, Cortes-Ibañez FO, van der Vegt B, Alizadeh BZ, de Bock GH.
Eur J Nutr. 2022; 61(1):317-327.
42. **Impact of Expert Center endoscopic assessment of confirmed LGD diagnosed in community hospitals.**
Nieuwenhuis E, van Munster S, Curvers WL, Weusten BLAM, Alvarez Herrero L, Bogte A, Alkhalaf A, Schenk BE, Koch AD, Spaander MCW, Tang TJ, Nagengast WB, Westerhof J, Houben MHMG, Bergman JJ, Schoon EJ, Pouw RE.
Endoscopy. 2022; 54(10):936-944.

43. **Expression of proteins associated with the Warburg-effect and survival in colorectal cancer.**
Offermans K, Jenniskens JC, Simons CC, Samarska I, Fazzi GE, Smits KM, Schouten LJ, Weijenberg MP, Grabsch HI, van den Brandt PA.
J Pathol Clin Res. 2022; 8(2):169-180.
44. **Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.**
Ouahoud S, Jacobs RJ, Kodach LL, Voorneveld PW, Hawinkels LJAC, Weil NL, van Vliet B, Herings RM, van der Burg LRA, van Wezel T, Morreau H, Slingerland M, Bastiaannet E, Putter H, Hardwick JCH.
Br J Cancer. 2022; 126(2):297-301.
45. **Results of histopathological revisions of major salivary gland neoplasms in routine clinical practice.**
Reerds STH, Uijen MJM, Van Engen-Van Grunsven ACH, Marres HAM, van Herpen CML, Honings J.
J Clin Pathol. 2022; [Online ahead of print]
46. **The ADENO study: ADenomyosis and its Effect on Neonatal and Obstetric outcomes: a retrospective population-based study.**
Rees C, van Vliet H, Siebers A, Bulten J, Huppelschoten A, Westerhuis M, Mischi M, Schoot B.
Am J Obstet Gynecol. 2022; [Online ahead of print]
47. **Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the Netherlands.**
Reumkens A, Sastrowijoto P, Grabsch HI, Goudkade D, le Clercq C, Bakker M, Keulen E, de Ridder R, de Herder WW, Winkens B, Sanduleanu S, de Vos-Geelen J, Masclee A.
Endosc Int Open. 2022; 10(7):E940-E951.
48. **Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer.**
Rigter LS, Snaebjornsson P, Rosenberg EH, Altena E, van Grieken NCT, Aleman BMP, Kerst JM, Morton L, Schaapveld M, Meijer GA, van Leeuwen FE, van Leerdam ME; PALGA group.
PLoS One. 2022; 17(7):e0270591.
49. **Association of histological features with laryngeal squamous cell carcinoma recurrences: a population-based study of 1502 patients in the Netherlands.**
Ruiter LN, van Dijk BAC, Bruggink AH, Doornaert PAH, Philippens MEP, de Bree R, van Gils CH, Willems SM.
BMC Cancer. 2022; 22(1):444.
50. **Limited impact of COVID-19 related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumor characteristics: A nationwide pathology registry analysis.**
Sangers TE, Wakkee M, Kramer-Noels EC, Nijsten T, Louwman MWJ, Jaspars EH, Hollestein L.
Br J Dermatol. 2022; 187(2):196-202.
51. **Reproductive and external hormonal factors and the risk of renal cell cancer in the Netherlands Cohort Study.**
Schouten LJ, van de Pol J, Kviatkovsky MJ, van den Brandt PA.
Cancer Epidemiol. 2022; 79:102171.

52. **Polymorphisms in the mTOR-PI3K-Akt pathway, energy balance-related exposures and colorectal cancer risk in the Netherlands Cohort Study.**
 Simons CCJM, Schouten LJ, Godschalk RWL, van Schooten FJ, Stoll M, Van Steen K, van den Brandt PA, Weijenberg MP.
BioData Min. 2022; 15(1):2.
53. **Laboratory variation in the grading of dysplasia of duodenal adenomas in familial adenomatous polyposis patients.**
 Soons E, Siersema PD, van Lierop LMA, Bisseling TM, van Kouwen MCA, Nagtegaal ID, van der Post RS, Atsma F.
Fam Cancer. 2022; [Online ahead of print]
54. **Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.**
 Steeghs EMP, Groen HJM, Schuurin E, Aarts MJ, Damhuis RAM, Voorham QJM; PATH consortium; Ligtenberg MJL, Grünberg K.
Lung Cancer. 2022; 167:87-97.
55. **Prognosis of pregnancy-associated breast cancer: inferior outcome in patients diagnosed during second and third gestational trimesters and lactation.**
 Suelmann BBM, Bakhuis CFJ, van Dooijeweert C, Verloop J, Zweemer R, Linn S, van der Wall E, van Diest PJ.
Breast Cancer Res Treat. 2022; 192(1):175-189.
56. **Evidence-Based Selection, Development, and Testing of a Tailored Strategy to Improve Standardized Structured Reporting in Pathology: A Multicenter Study.**
 Swillens JEM, Voorham QJM, Nagtegaal ID, Hermens RPMG.
Arch Pathol Lab Med. 2022; 146(12):1496-1507.
57. **Quality of surveillance impacts the colitis-associated advanced neoplasia risk: a multicenter case-control study.**
 Te Groen M, Derks M, den Broeder N, Peters C, Dijkstra G, de Vries A, Romkens T, Horjus C, de Boer N, de Jong M, Nagtegaal I, Derikx L, Hoentjen F.
Clin Gastroenterol Hepatol. 2022; [Online ahead of print]
58. **Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study.**
 Tokez S, Wakkee M, Kan W, Venables ZC, Mooyaart AL, Louwman M, Nijsten T, Hollestein LM.
J Am Acad Dermatol. 2022; 86(2):331-338.
59. **Risk factors for metastatic cutaneous squamous cell carcinoma: Refinement and replication based on 2 nationwide nested case-control studies.**
 Tokez S, Venables ZC, Hollestein LM, Qi H, Bramer EM, Rentroia-Pacheco B, van den Bos RR, Rous B, Leigh IM, Nijsten T, Mooyaart AL, Wakkee M.
J Am Acad Dermatol. 2022; 87(1):64-71.
60. **Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study.**
 van Barele M, Rieborn A, Heemskerk-Gerritsen BAM, Obdeijn IM, Koppert LB, Loo CE, Tollenaar RAEM, Ausems MGEM, van de Beek I, Berger LPV, de Boer M, van Hest LP, Kets CM, Rookus M; Hebon; Schmidt MK, Jager A, Hoening MJ.
Breast Cancer Res Treat. 2022; 194(1):159-170.
61. **Efficacy and Long-term Outcomes of Repeated Large Loop Excision of the Transformation Zone of the Cervix.**

- van de Sande AJM, Schreuder CM, van Baars R, Koeneman MM, Gerestein CG, Kruse AJ, van Kemenade FJ, Willemsen SP, van Beekhuizen HJ.
Obstet Gynecol. 2022; 139(3):417-422.
62. **Appendectomy and the subsequent risk of cancer: A prospective population-based cohort study with long follow-up.**
van den Boom AL, Lavrijssen BDA, Fest J, Ikram MA, Stricker BH, van Eijck CHJ, Ruiter R.
Cancer Epidemiol. 2022; 77:102120.
63. **The impact of a healthy lifestyle on the risk of esophageal and gastric cancer subtypes.**
van den Brandt PA.
Eur J Epidemiol. 2022; 37(9):931-945.
64. **Biomarker concordance between primary colorectal cancer and ovarian metastases: a Dutch cohort study.**
van der Meer R, Jeuken JWM, Bosch SL, van Erning FN, Simkens LHJ, de Hingh IHJT, Roumen RMH.
J Cancer Res Clin Oncol. 2022; [Online ahead of print]
65. **Ovarian metastases in young women with colorectal cancer: a retrospective multicenter cohort study.**
van der Meer R, Bakkers C, Wegdam JA, Lettinga T, Boerma EG, Aarts F, de Hingh IHJT, Roumen RMH.
Int J Colorectal Dis. 2022; 37(8):1865-1873.
66. **Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival.**
van der Voort A, Liefwaard MC, van Ramshorst MS, van Werkhoven E, Sanders J, Wesseling J, Scholten A, Vrancken Peeters MJTFD, de Munck L, Siesling S, Sonke GS.
Breast. 2022; 65:110-115.
67. **Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.**
Van Nyen T, Planque M, van Wagenveld L, Duarte JAG, Zaal EA, Talebi A, Rossi M, Körner PR, Rizzotto L, Moens S, De Wispelaere W, Baiden-Amisshah REM, Sonke GS, Horlings HM, Eelen G, Berardi E, Swinnen JV, Berkens CR, Carmeliet P, Lambrechts D, Davidson B, Agami R, Fendt SM, Annibaldi D, Amant F.
Nat Commun. 2022; 13(1):4578.
68. **Impact of COVID-19 pandemic on diagnostic pathology in the Netherlands.**
van Velthuisen MLF, van Eeden S, le Cessie S, de Boer M, van Boven H, Koomen BM, Roozkrans F, Bart J, Timens W, Voorham QJM.
BMC Health Serv Res. 2022; 22(1):166.
69. **Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images.**
Wetstein SC, de Jong VMT, Stathonikos N, Opdam M, Dackus GMHE, Pluim JPW, van Diest PJ, Veta M.
Sci Rep. 2022 ;12(1):15102.
70. **Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors.**

Ykema BLM, Breekveldt ECH, Carvalho B, van Wezel T, Meijer GA, Kerst M, Schaapveld M, van Leeuwen FE, Snaebjornsson P, van Leerdam ME.
Br J Cancer. 2022; 127(11):1991-1996.

Overige PALGA-gerelateerde publicaties

1. **Nationwide implementation of a multifaceted tailored strategy to improve uptake of standardized structured reporting in pathology: an effect and process evaluation.**
 Swillens JEM, Voorham QJM, Akkermans RP, Nagtegaal ID, Hermens RPMG.
Implement Sci. 2022; 17(1):52.

2. **COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study**
 Vigliar E, Pisapia P, Dello Iacovo F, Alcaraz-Mateos E, Alì G, Ali SZ, Baloch ZW, Bellevicine C, Bongiovanni M, Botsun P, Bruzzese D, Bubendorf L, Büttner R, Canberk S, Capitanio A, Casadio C, Cazacu E, Cochand-Priollet B, D'Amuri A, Davis K, Eloy C, Engels M, Fadda G, Fontanini G, Fulciniti F, Hofman P, Iaccarino A, Ieni A, Jiang XS, Kakudo K, Kern I, Kholova I, Linton McDermott KM, Liu C, Lobo A, Lozano MD, Malapelle U, Maleki Z, Michelow P, Mikula MW, Musayev J, Özgün G, Oznur M, Peiró Marqués FM, Poller D, Pyzlak M, Robinson B, Rossi ED, Roy-Chowdhuri S, Saieg M, Savic Prince S, Schmitt FC, Seguí Iváñez FJ, Štoos-Veić T, Sulaieva O, Sweeney BJ, Tuccari G, van Velthuysen ML, VanderLaan PA, Vielh P, Viola P, Voorham QJM, Weynand B, Zeppa P, Faquin WC, Pitman MB, Troncone G.
Cancer Cytopathol. 2022; 130(5):344-351.

3. **Establishment of the Dutch nationwide, interdisciplinary infrastructure and biobank for fundamental and translational ovarian cancer research: Archipelago of Ovarian Cancer Research (AOCR).**
 Zelisse HS, van Gent M, de Ridder S, van der Aa MA, van Altena AM, Bart J, Belien JAM, Boere IA, Bosch SL, Broeks A, Bulten J, Collée M, Groenendijk FH, Horlings H, Jansen MPH, Jonges GN, Kooreman L, de Kroon CD, Lambrechts S, Lok C, Piek JM, Reyners AKL, Roes EM, Simons M, Wisman G, Yigit R, Zweemers R, Mom CH, van de Vijver MJ, Dijk F.
Gynecol Obstet Invest. 2022; 87(6):389-397.